Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
Adaptive Biotechnologies (Nasdaq: ADPT) announced that its next-generation sequencing clonoSEQ® MRD test is featured in 89 abstracts, including 36 oral presentations, at the 67th ASH Annual Meeting scheduled for Dec. 6–9, 2025 in Orlando.
Abstracts cover multiple myeloma, ALL, CLL, MCL, DLBCL and other blood cancers, with more than 17 presentations showing clonoSEQ informing real-world treatment decisions and expanded use in clinical trials across modalities such as CAR T and bispecific antibodies.
Adaptive Biotechnologies (Nasdaq: ADPT) ha annunciato che il suo test di MRD clonoSEQ® di nuova generazione è presente in 89 abstract, tra cui 36 presentazioni orali, al 67° ASH Annual Meeting in programma dal 6–9 dicembre 2025 a Orlando.
Gli abstract coprono multiplo mieloma, ALL, CLL, MCL, DLBCL e altri tumori del sangue, con oltre 17 presentazioni che mostrano come clonoSEQ informi decisioni di trattamento nel mondo reale e l'espansione dell'uso in studi clinici attraverso modalità come CAR-T e anticorpi bispecifici.
Adaptive Biotechnologies (Nasdaq: ADPT) anunció que su prueba de MRD clonoSEQ® de próxima generación está presente en 89 resúmenes, incluyendo 36 presentaciones orales, en la 67.ª Reunión Anual de ASH que se celebrará del 6 al 9 de diciembre de 2025 en Orlando.
Los resúmenes cubren mieloma múltiple, ALL, CLL, MCL, DLBCL y otros cánceres de sangre, con más de 17 presentaciones que muestran que clonoSEQ informa decisiones de tratamiento en el mundo real y la expansión de su uso en ensayos clínicos a través de modalidades como CAR-T y anticuerpos bispecíficos.
Adaptive Biotechnologies (나스닥: ADPT)는 차세대 시퀀싱 clonoSEQ® MRD 검사 핗이 89개 초록에 수록되었으며, 그 중 36건 구연 발표가 포함되어, 올랜도에서 열리는 67번째 ASH 연례 회의에서 2025년 12월 6–9일에 개최될 예정이라고 발표했습니다.
초록은 다발성 골수종, ALL, CLL, MCL, DLBCL 및 기타 혈액암을 다루며, 17건 이상의 발표에서 clonoSEQ가 실제 임상 의사 결정에 정보를 제공하고 CAR-T 및 이중 특이 항체와 같은 방법으로 임상 시험에서의 사용이 확장되고 있음을 보여줍니다.
Adaptive Biotechnologies (Nasdaq : ADPT) a annoncé que son test MRD clonoSEQ® de nouvelle génération est présent dans 89 résumés, dont 36 communications orales, lors de la 67e Réunion annuelle de l’ASH qui se tiendra du 6 au 9 décembre 2025 à Orlando.
Les résumés couvrent le myélome multiple, ALL, CLL, MCL, DLBCL et d'autres cancers du sang, avec plus de 17 présentations montrant que clonoSEQ informe les décisions de traitement dans le monde réel et l’utilisation élargie dans les essais cliniques via des modalities telles que CAR-T et les anticorps bispécifiques.
Adaptive Biotechnologies (Nasdaq: ADPT) gab bekannt, dass sein Next-Generation-Sequencing-clonoSEQ®-MRD-Test in 89 Abstracts enthalten ist, darunter 36 mündliche Präsentationen, auf der 67. ASH-Jahresversammlung, die vom 6. bis 9. Dezember 2025 in Orlando stattfindet.
Die Abstracts decken multiples Myelom, ALL, CLL, MCL, DLBCL und andere Bluterkrankungen ab, wobei mehr als 17 Präsentationen zeigen, dass clonoSEQ Behandlungsentscheidungen in der realen Welt informiert und der Einsatz in klinischen Studien über Modalitäten wie CAR-T und bispezifische Antikörper erweitert wird.
Adaptive Biotechnologies (ناسداك: ADPT) أعلنت أن اختبار MRD clonoSEQ® من الجيل التالي مدرج في 89 ملخصاً، بما في ذلك 36 عرضاً شفوياً، في الاجتماع السنوي الـ67 لـ ASH المزمع عقده في الفترة من 6 إلى 9 ديسمبر 2025 في أورلاندو.
تغطي الملخصات سرطان الدم المتعدد، ALL، CLL، MCL، DLBCL وغيرها من سرطانات الدم، مع أكثر من 17 عرضاً يبيّنون أن clonoSEQ يزوّد قرارات العلاج في العالم الحقيقي وتوسيع استخدامه في التجارب السريرية عبر طرائق مثل CAR-T والأجسام المضادة ثنائية التخصيص.
- None.
- None.
Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug development
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology (ASH) taking place Dec. 6–9, 2025, in Orlando.
Key highlights include:
- Abstracts featuring clonoSEQ MRD data span multiple myeloma (MM), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and other blood cancers, underscoring its position as the most widely used and validated next-generation sequencing-based MRD test in lymphoid malignancies.
- More than 17 presentations demonstrate how clonoSEQ MRD assessment is informing patient treatment decisions in real world clinical practice, including studies to guide treatment in ALL, CLL, MM, MCL and DLBCL.
- Continued expansion of clonoSEQ use in clinical trials to enable the deepest assessment of treatment responses for novel regimens and across a wide range of therapeutic modalities, including CAR T, bispecific antibodies, and other targeted therapies.
“It’s energizing to see the breadth of ASH presentations incorporating clonoSEQ this year, highlighting how integral MRD testing has become in patient care and clinical research across hematologic oncology,” said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. “This momentum reflects the multifaceted role MRD is playing in modern lymphoid cancer care—from guiding treatment decisions to accelerating therapeutic innovation.”
A complete list of the accepted abstracts featuring clonoSEQ is available here.
About clonoSEQ®
clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.
clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.
clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com
FAQ
How many abstracts feature clonoSEQ MRD testing at ASH 2025 for ADPT?
When and where will ADPT-related clonoSEQ presentations occur at the 67th ASH Annual Meeting?
Which blood cancers are covered by clonoSEQ MRD data in ADPT abstracts at ASH 2025?
How many ADPT presentations show clonoSEQ informing real-world treatment decisions at ASH 2025?
Is clonoSEQ being used in clinical trials presented by ADPT at ASH 2025?
What does the ADPT ASH 2025 presence suggest about clonoSEQ's role in hematologic oncology?
